奥氮平治疗首发精神分裂症40例临床观察

摘要

Objective To find out the curative effect and safety of Olanzapine in treatment of first episode schizophrenia, to gudie reasonable drug in clinic.Methods To choose 40 cases of first occur episode schizophrenia patients in our hospital during January 2012-November 2014, and to apply olanzapine only to achieve therapy; observe the effects for 8 weeks. We adopt BPRS to judge the clinical effectiveness, at the same time do the record on side reaction.Results Through the treatment of olanzapine, clinical recovered 36 patients(90%); upturned 3 patients(7.5%); no effected 1 patients (2.5%), there is not obvious side reaction, and the adverse reaction is not that serious.ConclusionOlanzapine has a better curative effects and with well safety, milder side effect, and the patients have much better compliance in the process of treating on schizophrenia, so it is worth to widely usage on clinical therapy.%目的：观察奥氮平（江苏豪森药业生产，商品名为欧兰宁）治疗首发精神分裂症的疗效及安全性，以指导临床合理用药。方法选取2012年1月至2014年11月在我院住院治疗首发精神分裂症的40例为研究对象，单独采用奥氮平进行治疗，临床观察持续8周。采用BPRS评定临床疗效，并记录下不良反应发生情况。结果经奥氮平治疗，临床痊愈36例（90%）；好转3例（7.5%）；无效1例（2.5%），不良反应少且程度轻。结论应用奥氮平治疗首发精神分裂症疗效显著，且无明显的不良反应发生，患者依从性良好，值得临床推广使用。